How are you feeling today? Keep up to date on news and stories related to health care here!
The sputtering economic rebound went into reverse in President Trump’s last full month in office, as employers laid off workers amid rising virus cases. — NYT: Top Stories
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2020 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 4. During the
Deaths reported across the country on Wednesday set a new record. Five states have now reported their millionth case. — NYT: Top Stories
Is it wiser to hold back the second doses everyone will need, or to give as many people as possible a shot now? There are concerns due to a supply constraint. Only Pfizer and Moderna vaccines are authorized, even though policymakers had
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients
The virus has taken the life of a young American teacher who became famous for a 2018 video of her students. Meanwhile, confusion and shortages impede some U.S. vaccination campaigns. And, India has approved the Oxford-AstraZeneca vaccine and a local version.
Health workers participate in a COVID-19 vaccine delivery system trial in Hyderabad, India, Saturday, Jan. 2, 2021. India tested its COVID-19 vaccine delivery system with a nationwide trial on Saturday as it prepares to roll-out an inoculation program to stem the coronavirus
Other cases involving the highly contagious variant that was first identified in Britain have been found in Colorado, California, and now Florida. — NYT: Top Stories
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies remains under review